title: Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary gamma-radiation. Integrilin WRIST.
abstract: The Integrilin Washington Radiation for In-Stent Restenosis Trial (WRIST) aimed to study the impact of IIb/IIIa inhibitors as adjunct therapy to intracoronary radiation therapy (IRT) for patients with in-stent restenosis (ISR). The impact of GP IIb/IIIa inhibitor (eptifibatide) as adjunct therapy to vascular brachytherapy using (192)Ir emitter was examined in patients with in-stent restenosis. In the study, 150 patients were assigned to eptifibatide (Integrilin) and 150 patients to heparin only. Clinical composite endpoints at 30 days were similar between the patients treated with and without eptifibatide (4.7% vs. 4.0%; P = 0.78). There was a similarity in the non-Q-wave myocardial infarction (MI) rates between the eptifibatide and the control group. Major bleeding was similar in patients treated with and without eptifibatide. Overall, the use of eptifibatide as adjunct therapy for patients with ISR that are treated with IRT did not impact the clinical outcome at 30 days.
authors.affiliation: Cardiology Research Institute, Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA. ron.waksman@medstar.net
authors.forename: Ron
authors.initials: R
authors.lastname: Waksman
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Ajani
authors.forename: Luis
authors.initials: L
authors.lastname: Gruberg
authors.forename: Ellen
authors.initials: E
authors.lastname: Pinnow
authors.forename: Afework
authors.initials: A
authors.lastname: GebreEyesus
authors.forename: Regina
authors.initials: R
authors.lastname: Deible
authors.forename: Lowell F
authors.initials: LF
authors.lastname: Satler
authors.forename: Augusto D
authors.initials: AD
authors.lastname: Pichard
authors.forename: Rebecca
authors.initials: R
authors.lastname: Torguson
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Kent
authors.forename: William
authors.initials: W
authors.lastname: Suddath
authors.forename: Joseph
authors.initials: J
authors.lastname: Lindsay
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D019917:Blood Vessel Prosthesis Implantation; D001918:Brachytherapy; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D018592:Cross-Over Studies; D000077542:Eptifibatide; D005260:Female; D005720:Gamma Rays / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy; D010455:Peptides / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D007527:Isoenzymes; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D000077542:Eptifibatide